Gaudium IVF and Women Health Limited has announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors approved the financial results, noted a variation in the objects of its Initial Public Offer (IPO) fund utilization, and appointed Dr. Ravish Manchanda as National Head – Operations Expansion & Strategy. The company also updated on its planned expansion of IVF centers and its financial performance.
Gaudium IVF Announces Q2 FY27 Financial Results and Key Updates
Gaudium IVF and Women Health Limited has officially disclosed its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors, at a meeting held on November 12, 2026, considered and approved these results, along with several other significant corporate actions.
Financial Highlights
The company reported its unaudited standalone and consolidated financial results for the period. The unaudited financial results, along with the Limited Review Report from the Statutory Auditors, M/s. SKGN & Associates LLP, have been submitted. Key financial figures for the standalone statement of profit and loss show a profit for the period/year of ₹819.97 lakhs, with total comprehensive income amounting to ₹822.38 lakhs.
IPO Fund Utilization Variation
A key decision made by the Board was the approval of a variation in the objects of the Initial Public Offer (IPO). This variation pertains to Object No. 1, the establishment of 19 New IVF Centres, involving changes in 6 cities/locations and a revision of the establishment schedule, with all centers to be established by Fiscal 2029. This proposed variation requires shareholder approval via a Special Resolution through Postal Ballot. The total funds earmarked for this object remain unchanged at ₹5,000.00 Lakhs.
Appointment of Senior Management Personnel
In a significant move to bolster its leadership, the company announced the appointment of Dr. Ravish Manchanda as the National Head – Operations Expansion & Strategy. He has been designated as a Senior Management Personnel (SMP) of the Company, effective from November 12, 2026. Dr. Manchanda brings over 15 years of experience in the healthcare sector, specializing in IVF and fertility operations.
Policy Amendment
Furthermore, the Board approved an amendment to the Policy on Code of practices and procedures for fair disclosure of unpublished price sensitive information, aligning with SEBI (Prohibition of Insider Trading) Regulations, 2015. The amended policy will be available on the company’s website.
IPO Proceeds Utilization
Details on the utilization of IPO proceeds reveal that as of September 30, 2026, a total of ₹5,065.20 Lakhs has been utilized from the gross proceeds of ₹9,000.08 Lakhs. The unutilized proceeds, amounting to ₹3,988.04 Lakhs, are held in various bank accounts, including fixed deposits with HDFC Bank and a current account with Axis Bank.
Source: BSE
